P selectin inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 24 hours
DelveInsight’s, “P selectin inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in P selectin inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
P selectin inhibitors: Overview
P-Selectin (CD62P), previously termed PADGEM or GMP-140, is a single chain glycoprotein of 140 kDa expressed in platelets and endothelial cells. In platelets, P-selectin is stored in ? granules, whereas in endothelial cells it is found in Weibel–Palade bodies. P-selectin mediates the rolling of blood cells on the surface of the endothelium and initiates the attachment of leukocytes circulating in the blood to platelets, endothelial cells, and other leukocytes at sites of tissue injury and inflammation. P-selectin plays a key role in diseases associated with injury and arterial thrombosis. Increased expression of P-selectin is observed in coronary artery disease, acute myocardial infarction, stroke, and peripheral artery diseases. Increased level of sP-selectin and elevated P-selectin expression may be good markers of some types of carcinoma, such as neoplastic pulmonary diseases, breast, renal, and colon cancer, and blood cancer. P-selectin inhibition with protein therapeutics such as antibodies or soluble ligands given intravenously can decrease thrombosis in a mouse ligation model of venous thrombosis. Inhibition of P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) play a key role in proliferation of Multiple myeloma.
Report Highlights
This segment of the P selectin inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
P selectin inhibitors Emerging Drugs
Further product details are provided in the report……..
P selectin inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different P selectin inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
P selectin inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses P selectin inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging P selectin inhibitors drugs.
P selectin inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “P selectin inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in P selectin inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
P selectin inhibitors: Overview
P-Selectin (CD62P), previously termed PADGEM or GMP-140, is a single chain glycoprotein of 140 kDa expressed in platelets and endothelial cells. In platelets, P-selectin is stored in ? granules, whereas in endothelial cells it is found in Weibel–Palade bodies. P-selectin mediates the rolling of blood cells on the surface of the endothelium and initiates the attachment of leukocytes circulating in the blood to platelets, endothelial cells, and other leukocytes at sites of tissue injury and inflammation. P-selectin plays a key role in diseases associated with injury and arterial thrombosis. Increased expression of P-selectin is observed in coronary artery disease, acute myocardial infarction, stroke, and peripheral artery diseases. Increased level of sP-selectin and elevated P-selectin expression may be good markers of some types of carcinoma, such as neoplastic pulmonary diseases, breast, renal, and colon cancer, and blood cancer. P-selectin inhibition with protein therapeutics such as antibodies or soluble ligands given intravenously can decrease thrombosis in a mouse ligation model of venous thrombosis. Inhibition of P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) play a key role in proliferation of Multiple myeloma.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence P selectin inhibitors R&D. The therapies under development are focused on novel approaches for P selectin inhibitors.
This segment of the P selectin inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
P selectin inhibitors Emerging Drugs
- DSTAT: Chimerix
- Inclacumab: Global Blood Therapeutics
Further product details are provided in the report……..
P selectin inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different P selectin inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on P selectin inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
P selectin inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses P selectin inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging P selectin inhibitors drugs.
P selectin inhibitors Report Insights
- P selectin inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing P selectin inhibitors drugs?
- How many P selectin inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for P selectin inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the P selectin inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for P selectin inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Chimerix
- Novartis
- GlycoMimetics
- Modus Therapeutics
- Global Blood Therapeutics
- Suzhou Ronnsi Pharma
- DSTAT
- Crizanlizumab
- Rivipansel
- Sevuparin
- Inclacumab
- Depolymerised holothurian glycosaminoglycan
Introduction
Executive Summary
P selectin inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
P selectin inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
P selectin inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
P selectin inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
DSTAT: Chimerix
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Crizanlizumab: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Inclacumab: Global Blood Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Depolymerised holothurian glycosaminoglycan: Suzhou Ronnsi Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
P selectin inhibitors Key Companies
P selectin inhibitors Key Products
P selectin inhibitors- Unmet Needs
P selectin inhibitors- Market Drivers and Barriers
P selectin inhibitors- Future Perspectives and Conclusion
P selectin inhibitors Analyst Views
P selectin inhibitors Key Companies
Appendix
Executive Summary
P selectin inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
P selectin inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
P selectin inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
P selectin inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
DSTAT: Chimerix
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Crizanlizumab: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Inclacumab: Global Blood Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Depolymerised holothurian glycosaminoglycan: Suzhou Ronnsi Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
P selectin inhibitors Key Companies
P selectin inhibitors Key Products
P selectin inhibitors- Unmet Needs
P selectin inhibitors- Market Drivers and Barriers
P selectin inhibitors- Future Perspectives and Conclusion
P selectin inhibitors Analyst Views
P selectin inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for P selectin inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for P selectin inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for P selectin inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for P selectin inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products